Tag: oncology
Bayer: Collaboration with Thermo Fisher in oncology
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
AstraZeneca: acquisition of Fusion in precision oncology
(CercleFinance.com) – AstraZeneca announced on Tuesday that it would take control of the Canadian company Fusion Pharmaceuticals, specializing in precision cancer drugs, in a transaction worth up to $2.4 billion.…
Pfizer: Eight oncology blockbusters planned by 2030
Read also (CercleFinance.com) – Pfizer estimated on Thursday that it had a ‘robust’ portfolio of drugs in oncology since the finalization of the acquisition of Seagen at the end of…
Celyad Oncology announces its intention to terminate its SEC reporting obligations – 02/08/2024 at 10:01 p.m.
Mont-Saint-Guibert, Belgium, February 8, 2024, 10:01 p.m. CET – privileged and regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that the Company will voluntarily…
Celyad Oncology provides an update on activities for the fourth quarter of 2023 and presents its outlook for 2024 – 01/16/2024 at 10:01 p.m.
Mont-Saint-Guibert, Belgium; January 16, 2024, 10:01 p.m. CET – Celyad Oncology (Euronext: CYAD) (the “Company”), today publishes an update of its activities for the fourth fiscal quarter of 2023, as…
Merck and co inc: Acquisition of Harpoon to strengthen its position in oncology
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Sofinnova Partners and Gustave Roussy announce a strategic partnership to boost the acceleration of French oncology startups
(Boursier.com) — Sofinnova Partners (“Sofinnova”), a leading venture capital company in Europe specializing in life sciences and based in Paris, London and Milan, Gustave Roussy, the leading cancer center in…
MaaT Pharma, leader in the development of drugs based on intestinal microbiota in oncology, receives funding from the State for the clinical development of MaaT033 as part of the France 2030 Plan – 11/30/2023 at 6:05 p.m.
MaaT Pharma, leader in the development of drugs based on intestinal microbiota in oncology, receives funding from the State for the clinical development of MaaT033 as part of the France…
Celyad Oncology: cash flow of 2.3 million, visibility until the 1st quarter of 2024 – 09/11/2023 at 1:35 p.m.
(AOF) – Celyad Oncology announces that as of September 30, 2023, it had cash and cash equivalents of 2.3 million euros. The biotech specializing in chimeric antigen receptor T cell…
Immunology and oncology: AstraZeneca signs an agreement with the French Cellectis – 01/11/2023 at 11:24
The British pharmaceutical giant AstraZeneca announced on Wednesday “a collaboration and investment agreement with Cellectis”, a French biotechnology company, which should enable the development of new products “in immunology, oncology…
France represents “13% of global clinical trials in oncology”, a platform created to list them
Romain Rouillard 8:00 p.m., October 10, 2023modified to 11:39 a.m., October 11, 2023 France, world champion in the fight against cancer? In any case, France is setting itself up as…
Eiffage begins work on the future oncology building within the Grand Parc Campus in Villejuif
By Alexandra Saintpierre Published on 10/23/2023 at 8:43 p.m. Photo credit © Eiffage (Boursier.com) — Eiffage through its…